A cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countries
Background: Two COVID-19 oral antivirals (COAVs), Molnupiravir and Paxlovid, have been shown to be cost-effective in high-income countries. Aim: This study assesses the cost-effectiveness of Paxlovid and Molnupiravir, compared to usual care in three African countries. Setting: The study was conduc...
Saved in:
| Main Authors: | Ijeoma P. Edoka, Tom Drake, Peter Baker, Raji Tajudeen, Elias Asfaw, Javier Guzman, Nicaise Ndembi, Justice Nonvignon, Jean Kaseya |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2025-06-01
|
| Series: | Journal of Public Health in Africa |
| Subjects: | |
| Online Access: | https://publichealthinafrica.org/index.php/jphia/article/view/805 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
by: Franco Wing Tak Cheng, et al.
Published: (2024-05-01) -
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01) -
Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study
by: Rani Sawtell, et al.
Published: (2025-12-01) -
Paxlovid for the treatment of severe or critical COVID-19 in children
by: Linjuan Xiang, et al.
Published: (2025-07-01) -
Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study
by: Ivana I Gmizic, et al.
Published: (2024-05-01)